Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection
- PMID: 7768627
- PMCID: PMC173317
- DOI: 10.1128/iai.63.6.2382-2386.1995
Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection
Abstract
Mice immunized intransally or intragastrically with proteosome vaccines containing either Shigella sonnei or S. flexneri 2a lipopolysaccharide were protected against lethal pneumonia caused by homologous organisms in an experimental murine intranasal challenge model of Shigella infection. Histopathological analysis demonstrated that immunization also protected against the progressive lesions resulting from invasion of the pulmonary mucosa by S. sonnei. These data show that mucosal proteosome-lipopolysaccharide vaccines can protect against lethal bacterial pneumonia and indicate that such vaccines are promising candidates for protection against intestinal shigellosis.
Similar articles
-
Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.Infect Immun. 1993 Jun;61(6):2390-5. doi: 10.1128/iai.61.6.2390-2395.1993. Infect Immun. 1993. PMID: 8500877 Free PMC article.
-
Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis.J Exp Med. 1995 Sep 1;182(3):769-78. doi: 10.1084/jem.182.3.769. J Exp Med. 1995. PMID: 7544397 Free PMC article.
-
Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.Vaccine. 1999 Aug 6;17(23-24):3109-15. doi: 10.1016/s0264-410x(99)00136-x. Vaccine. 1999. PMID: 10462247 Clinical Trial.
-
An update on Shigella vaccines.Isr J Med Sci. 1994 May-Jun;30(5-6):495-7. Isr J Med Sci. 1994. PMID: 8034510 Review.
-
Shigellosis: the current status of vaccine development.Curr Opin Infect Dis. 2008 Jun;21(3):313-8. doi: 10.1097/QCO.0b013e3282f88b92. Curr Opin Infect Dis. 2008. PMID: 18448978 Review.
Cited by
-
Development of the Shigella flexneri 2a, 3a, 6, and S. sonnei artificial Invaplex (InvaplexAR) vaccines.mSphere. 2023 Aug 24;8(4):e0007323. doi: 10.1128/msphere.00073-23. Epub 2023 Jun 30. mSphere. 2023. PMID: 37389412 Free PMC article.
-
Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.Infect Immun. 1996 Nov;64(11):4686-93. doi: 10.1128/iai.64.11.4686-4693.1996. Infect Immun. 1996. PMID: 8890226 Free PMC article.
-
Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.Infect Immun. 1999 Feb;67(2):921-7. doi: 10.1128/IAI.67.2.921-927.1999. Infect Immun. 1999. PMID: 9916109 Free PMC article.
-
Nasal immunization with Burkholderia multivorans outer membrane proteins and the mucosal adjuvant adamantylamide dipeptide confers efficient protection against experimental lung infections with B. multivorans and B. cenocepacia.Infect Immun. 2007 Jun;75(6):2740-52. doi: 10.1128/IAI.01668-06. Epub 2007 Feb 12. Infect Immun. 2007. PMID: 17296759 Free PMC article.
-
From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine's Refinement and Evolution.Vaccines (Basel). 2022 Apr 1;10(4):548. doi: 10.3390/vaccines10040548. Vaccines (Basel). 2022. PMID: 35455297 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources